Citius Oncology, Inc. Income Statement

Income Statement Sep2024 Sep2025
Revenue & cost
Revenue -0.22M
Operating items
Research & Development 4.93M6.42M
Selling, General & Administrative 8.15M8.78M
Restructuring Costs 1.85M2.20M
Other Operating Expenses 5.65M6.12M
Operating Expenses 20.57M23.52M
Operating Income -20.57M-23.52M
EBIT -20.57M-23.52M
Non-operating items
Interest & Investment Income 0.04M
Non Operating Income -0.18M
Net income details
EBT -20.57M-23.70M
Tax Provisions 0.58M1.06M
Profit After Tax -21.15M-24.76M
Income from Continuing Operations -21.15M-24.76M
Consolidated Net Income -21.15M-24.76M
Income towards Parent Company -21.15M-24.76M
Net Income towards Common Stockholders -21.15M-24.76M
Additional items
EPS (Basic) -0.31-0.34
EPS (Weighted Average and Diluted) -0.31-0.34
Shares Outstanding (Weighted Average) 71.72M78.37M
EBITDA -20.57M-23.52M
Interest Expenses 0.22M